Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (21-30 of 101) with videos related to

Pageof 11
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12J A Gollob, K G Veenstra, J W Mier, et al.
The American Journal of Medicine|April 1, 1992
Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case reportN P Sauter, M B Atkins, J W Mier, et al.
Urology|December 18, 2001
Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgeryJ A Gollob, M P Upton, W C DeWolf, et al.
Journal of the American Society of Nephrology : JASN|April 1, 1995
Rapidly progressive glomerulonephritis after immunotherapy for cancerM G Parker, M B Atkins, A A Ucci, et al.
Journal of Clinical & Laboratory Immunology|April 1, 1990
Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapyR W Bergstrom, M B Atkins, J W Mier, et al.
Chest|March 1, 1992
Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parametersP J Vogelzang, S M Bloom, J W Mier, et al.
Blood|January 1, 1994
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55H Tilg, E Trehu, M B Atkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1993
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimeraH Tilg, L Shapiro, M B Atkins, et al.
Blood|August 15, 1995
Interleukin-6-associated anemia: determination of the underlying mechanismM B Atkins, K Kappler, J W Mier, et al.
The Journal of Urology|October 23, 1997
Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinomaM L Fallick, D F McDermott, D LaRock, et al.
Pageof 11

Showing results (21-30 of 101) with videos related to

Sort By:
Pageof 11
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12J A Gollob, K G Veenstra, J W Mier, et al.
The American Journal of Medicine|April 1, 1992
Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case reportN P Sauter, M B Atkins, J W Mier, et al.
Urology|December 18, 2001
Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgeryJ A Gollob, M P Upton, W C DeWolf, et al.
Journal of the American Society of Nephrology : JASN|April 1, 1995
Rapidly progressive glomerulonephritis after immunotherapy for cancerM G Parker, M B Atkins, A A Ucci, et al.
Journal of Clinical & Laboratory Immunology|April 1, 1990
Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapyR W Bergstrom, M B Atkins, J W Mier, et al.
Chest|March 1, 1992
Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parametersP J Vogelzang, S M Bloom, J W Mier, et al.
Blood|January 1, 1994
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55H Tilg, E Trehu, M B Atkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1993
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimeraH Tilg, L Shapiro, M B Atkins, et al.
Blood|August 15, 1995
Interleukin-6-associated anemia: determination of the underlying mechanismM B Atkins, K Kappler, J W Mier, et al.
The Journal of Urology|October 23, 1997
Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinomaM L Fallick, D F McDermott, D LaRock, et al.
Pageof 11